Ipca Laboratories Limited Announces Board Meeting Outcome for Appointment Of Dr. Narendra Mairpady (DIN 00536905) As A Director / Independent Director
October 20, 2022 at 10:57 am IST
Share
Ipca Laboratories Limited appointed Dr. Narendra Mairpady (DIN 00536905) as an Additional Director of the Company with effect from 20th October, 2022. He is also appointed as an Independent Director of the Company for a period of 5 years from 20th October, 2022 till 19th October, 2027. This appointment is subject to the approval of shareholders.
Dr. Narendra Mairpady, aged 68 years, is a Commerce Graduate and also holds a Bachelor of Law Degree from Mysore University. He is also a certified CAIIB from the Institure of Banking. He has also obtained his Doctor Letters from Hindustan University, Chennai and Kalpagam University, Coimbatore.
Consequent to the above, the revised composition of the Board of Directors of the Company with effect from 20th October, 2022 will be: Mr. Premchand Godha- Chairman & Managing Director /CEO; Mr. A.K. Jain- Joint Managing Director /CFO; Mr. Pranay Godha- Executive Director; Mr. Prashant Godha Executive Director; Mr. Anand T. Kusre - Independent Director; Dr. (Ms.) Manisha Premnath Independent Director; Mr. Kamal Kishore Seth - Independent Director; Dr. Narendra Mairpady - Independent Director. The Board has also re-constituted its following committees with effect from 20th October, 2022 and the revised Board Committees will now comprise of the following Board Members: Audit Committee; Mr. Anand T. Kusre - Chairman of the Committee /Independent Director; Mr. Kamal Kishore Seth - Independent Director; Dr. Narendra Mairpady - Independent Director; Mr. Prashant Godha - Executive Director; Nomination and Remuneration Committee: Mr. Anand T. Kusre Chairman of the Committee /Independent Director; Mr. Kamal Kishore Seth - Independent Director; Dr. (Ms.) Manisha Premnath - Independent Director; Dr. Narendra Mairpady - Independent Director.
Ipca Laboratories Limited is an India-based integrated pharmaceutical company. The Company is manufacturing and marketing over 350 formulations and approximately 80 active pharmaceutical ingredients (APIs) covering various therapeutic segments. It offers APIs, such as Atenolol, Chloroquine Phosphate, Chlorthalidone, Furosemide, Hydroxychloroquine sulfate, Losartan, Metoprolol Succinate, Metoprolol Tartrate, Pyrantel Salts and Propranolol. The Company offers brands, such as Zerodol, Lariago, HCQS, Perinorm, Rapither AB, Tenoric, Lumerax, Etova, Fexova, Malirid, Allsuth, Alwiz, AZR 50mg, Bacilon, Cinkona, Clarbact, Glyree MV, Halotop, Luliz, Ozepam, Pacimol, Pari, Xtor-F, Zabpro, Zilast, Ramcor, Sove, Venpower and Folitrax. The products of the Company are sold in over 100 countries across the globe. The Company has 18 manufacturing units in India manufacturing APIâs and formulations. Its subsidiaries include Ipca Pharmaceuticals, Inc., Ipca Pharma Nigeria Ltd., Trophic Wellness Pvt. Ltd.